- Home
- PRT vs IGC Comparison
PRT vs IGC Comparison
Compare PRT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | IGC |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 27.7M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | PRT | IGC |
|---|---|---|
| Price | $2.20 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 25.6K | ★ 639.5K |
| Earning Date | 05-13-2026 | 03-19-2026 |
| Dividend Yield | ★ 13.45% | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.82 | $0.24 |
| 52 Week High | $4.12 | $0.50 |
Technical Indicators
Market Signals| Indicator | PRT | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 56.92 |
| Support Level | $2.02 | $0.28 |
| Resistance Level | $2.34 | $0.31 |
| Average True Range (ATR) | 0.07 | 0.01 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 29.03 | 68.94 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.